iRadimed Corp. (IRMD)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-15
$82.41-0.15%
Close 2026-09-15 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-15
Research Workspace
Put IRMD beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (4q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Maintain revenue growth trajectory near guidance: FY26 revenue guidance mid $93.5M vs target $93.5M; low $91.0M at trip threshold.
View ThesisRevenue is growing steadily — about 11% over the past year.
View GrowthManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet, guidance credibility, market reaction to earnings.
View ManagementExpectations look high — the market is pricing in about 29% growth a year, above the roughly 13% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskIRMD's revenue growth trajectory must maintain guidance near $93.5 million to justify its price. Revenue grew 0.5% year over year, and the last quarter beat expectations. It trades at 43× P/E versus a peer median of 28×, indicating the market prices in more growth than forecast. The primary risk is the pressure on revenue growth, with a 31% probability of missing outlook. Peer multiples imply a price about 29% below where it trades (it looks expensive on this basis).
Trailing returns as of 2026-09-15. IRMD is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 2 analysts currently covering IRMD (as of Sep 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare IRMD with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| IRMD Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-15. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put IRMD next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
CEO selling stock may raise concerns about leadership stability.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-15. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Maintain revenue growth trajectory
Q1 report highlights revenue growth, supporting objectives.
CEO's stock sale may indicate lack of confidence.